Open AccessStereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis
Author(s) -
Dominik Bettinger,
David J. Pinato,
Michael Schultheiß,
Rohini Sharma,
Lorenza Rimassa,
Tiziana Pressiani,
Michela Emma Burlone,
Mario Pirisi,
Masatoshi Kudo,
Joong-Won Park,
Nico Buettner,
Christoph NeumannHaefelin,
Tobias Böettler,
N. Abbasi-Senger,
H. Alheit,
Wolfgang Baus,
Oliver Blanck,
S. Gerum,
Matthias Gückenberger,
Daniel Habermehl,
C. Ostheimer,
Oliver Riesterer,
Jörg Tamihardja,
AncaLigia Grosu,
Robert Thimme,
Thomas Brunner,
Eleni Gkika
Publication year - 2018
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000490260
Subject(s) - medicine , sorafenib , hepatocellular carcinoma , propensity score matching , clinical endpoint , radiosurgery , retrospective cohort study , adverse effect , oncology , overall survival , radiation therapy , radiology , surgery , clinical trial
Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC.